Conoscere Clinical Research LLC is categorized under Medical Labs in East Syracuse, NY and active since 2012.
Conoscere Clinical Research LLC was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 621511 by the NAICS.
If you are seeking more information, feel free to contact Debra Greiner at the company’s single location by writing to 332 Summerhaven Drive North, East Syracuse, New York NY 13057 or by phoning (315) 632-6126. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Conoscere Clinical Research LLC |
| Contact Person: | Debra Greiner |
| Address: | 332 Summerhaven Drive North, East Syracuse, New York 13057 |
| Phone Number: | (315) 632-6126 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Medical Labs |
| SIC Code: | 8071 |
| NAICS Code: | 621511 |
| Share This Business: |
Conoscere Clinical Research LLC was started in 2012 to provide professional Medical Labs under the SIC code 8071 and NAICS code 621511. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Debra Greiner for inquiries that concern Conoscere Clinical Research LLC by calling the company number (315) 632-6126, as your correspondence is most welcome. Additionally, the physical location of the single location of Conoscere Clinical Research LLC can be found at the coordinates 43.050784,-76.013481 as well as the street address 332 Summerhaven Drive North in East Syracuse, New York 13057.
For its online presence, you may visit Conoscere Clinical Research LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.